Market News AIOpen the app

ACRS stock news · Aclaris Therapeutics, Inc.

Stories about Aclaris Therapeutics, Inc. (ACRS) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for ACRS

Follow Aclaris Therapeutics, Inc. (ACRS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ACRS
Free on the App Store and Google Play, or on the web.
  1. Oct 31, 2026, 10:15 AM ET · Opinion

    Canaccord Genuity increased its price target for Aclaris Therapeutics, keeping a 'Buy' rating.

    Good for ACRS

    Canaccord kept its Buy rating on Aclaris and raised its target price from $10 per share to $13 per share. This is a positive analyst signal, but the story reports no new company results.

  2. Aug 6, 2026, 6:22 PM ET · Market

    Aclaris Therapeutics, Inc. announces the establishment of a significant definitive agreement (ACRS).

    Neutral

    Aclaris Therapeutics has filed a Form 8-K indicating the entry into a material definitive agreement, which is a significant development that could lead to new opportunities for the company. This news is likely to be viewed positively by investors as it suggests potential growth or strategic advancements.